In the overlapping territory where metabolic disease meets respiratory illness, a year-long study of more than 16,000 Americans living with both asthma and type 2 diabetes has surfaced a humbling reminder that biological logic does not always yield clinical confirmation. Two incretin therapies — tirzepatide and semaglutide — produced nearly identical rates of asthma exacerbation despite tirzepatide's well-documented superiority in reducing weight and blood sugar, suggesting that the path from metabolic improvement to airway health may be longer, or more winding, than medicine had assumed. The